Published in

Elsevier, The Lancet Oncology, 12(8), p. 1079-1087

DOI: 10.1016/s1470-2045(07)70346-7

Links

Tools

Export citation

Search in Google Scholar

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)

Journal article published in 2007 by Jolien M. Bueno-De-Mesquita, Wim H. van Harten, Valesca P. Retel ORCID, Laura J. van 't Veer, Frits Sam van Dam, Kim Karsenberg, Kirsten Fl Douma, Harm van Tinteren ORCID, Johannes L. Peterse, Jelle Wesseling, Tin S. Wu, Douwe Atsma, Emiel Jt Rutgers, Guido Brink, Arno N. Floore and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

A microarray-based 70-gene prognosis signature might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of implementation of the 70-gene prognosis signature in community-based settings and its effect on adjuvant systemic treatment decisions when considered with treatment advice formulated from the Dutch Institute for Healthcare Improvement (CBO) and other guidelines.